CIK 0001620463
- Non-accelerated filer
- Smaller reporting company
LeonaBio, Inc.
Sign in to watch- Ticker
- LONA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 453368487
- Phone
- +1 425-620-8501
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Former names
- Athira Pharma, Inc., M3 Biotechnology, Inc.
- Open-market buys, last 90 days
- $9,919,161,281
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-03 | FLUKE JOHN M JR Director | Exercise or conversion | +25,220 | $1.19 | $30K | 140,101 |
| 2021-02-03 | FLUKE JOHN M JR Director | Exercise or conversion | +3,783 | $1.35 | $5K | 143,884 |
| 2021-02-03 | FLUKE JOHN M JR Director | Exercise or conversion · Stock Option (Right to Buy) | −25,220 | 0 | ||
| 2021-02-03 | FLUKE JOHN M JR Director | Exercise or conversion · Stock Option (Right to Buy) | −3,783 | 0 | ||
| 2021-01-25 | PERCEPTIVE ADVISORS LLC Director | Purchase | +311,111 | $22.50 | $7.0M | 3,425,916 |
| 2020-12-11 | Romano Kelly A Director | Grant or award · Stock Option (Right to Buy) | +27,742 | 27,742 | ||
| 2020-09-22 | EDELMAN JOSEPH Director | Conversion | +1,644,785 | 2,055,981 | ||
| 2020-09-22 | EDELMAN JOSEPH Director | Purchase | +1,058,824 | $17.00 | $18.0M | 3,114,805 |
| 2020-09-22 | EDELMAN JOSEPH Director | Conversion · Series B Preferred Stock | −1,644,785 | 0 | ||
| 2020-09-22 | FLUKE JOHN M JR Director | Conversion | +12,610 | 63,050 | ||
| 2020-09-22 | FLUKE JOHN M JR Director | Conversion | +51,831 | 114,881 | ||
| 2020-09-22 | FLUKE JOHN M JR Director | Conversion | +6,731 | 6,731 | ||
| 2020-09-22 | FLUKE JOHN M JR Director | Conversion · Series A Preferred Stock | −12,610 | 0 | ||
| 2020-09-22 | FLUKE JOHN M JR Director | Conversion · Series A-1 Preferred Stock | −51,831 | 0 | ||
| 2020-09-22 | FLUKE JOHN M JR Director | Conversion · Series B-1 Preferred Stock | −6,731 | 0 | ||
| 2020-09-22 | Litton Mark James Chief Operating Officer | Conversion | +13,126 | 63,566 | ||
| 2020-09-22 | Litton Mark James Chief Operating Officer | Conversion | +6,563 | 6,563 | ||
| 2020-09-22 | Litton Mark James Chief Operating Officer | Conversion | +6,563 | 6,563 | ||
| 2020-09-22 | Litton Mark James Chief Operating Officer | Conversion | +6,563 | 6,563 | ||
| 2020-09-22 | Litton Mark James Chief Operating Officer | Conversion · Series B Preferred Stock | −13,126 | 0 |
Page 17 of 18 · 349 trades